Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.58 |
| ▸ | ABL1 | P00519 | 11/20 | 0.58 |
| ▸ | HCK | P08631 | 11/20 | 0.58 |
| ▸ | SRC | P12931 | 11/20 | 0.58 |
| ▸ | KDR | P35968 | 11/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.58 |
| ▸ | MTOR | P42345 | 11/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.58 |
| ▸ | PRKDC | P78527 | 11/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.58 |
| ▸ | ITK | Q08881 | 3/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665835 | 1.00 | EGFR (0.58) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16655483 | 0.95 | ITK (0.64) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16665834 | 0.95 | ITK (0.64) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL23917228 | 0.89 | ITK (0.56) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16655946 | 0.88 | ITK (0.61) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16665831 | 0.88 | ITK (0.61) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16655619 | 0.87 | EGFR (0.60) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16665830 | 0.84 | BTK (0.52) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16655955 | 0.84 | BTK (0.52) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16655585 | 0.83 | EGFR (0.60) | EGFRABL1HCKSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | EGFR 828/4885PIK3CD 2/4885ABL1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.